ProQR Therapeutics (PRQR) Reports Q3 Net Loss of €12.4M
ProQR reported a Q3 2026 net loss of €12.4M, or €0.09 per diluted share, versus €11.0M, or €0.10, in Q3 2025. Cash was approximately €103.0M at September 30, 2026, versus €92.4M at December 31, 2025.Material DetailsContext by AI AnalystThis is a quarterly financial update alongside ongoing early-st…